Ligand Pharmaceuticals Incorporated (LGND) - NASDAQ
  • Jim Van Meerten | Send Message 25 Apr

    $LGND - 96% technical buy signals - 16 new highs and up 26.19% in the last month - Relative Strength Index 79.24%
      • Jim Van Meerten | Send Message 25 Apr

        5 Small Caps For Momentum Investors $LGND, $KRA, $ZEUS
          • Kareem Khaidi | Send Message 28 Mar

            Want To Own The Biopharma Industry? Buy Ligand Pharmaceuticals $LGND
            Reply (1)
            • BiotechX | Send Message 12 Apr
              : I like this stock - huge pipeline, increasing royalties and the new antibody technology makes LGND even more appealing.
              • Paul Johnson | Send Message 3 Mar

                Analyst upgrades: $BWLD upgraded to outperform, $DIS to overweight, $LGND started with buy, $SHW upgraded to buy.
                  • wilkinson99 | Send Message 22 Jan

                    Notable Movers at Noon: (Up) $VLO +6.1% $LGND +5.2% $TLGT +3.7% $LII +3.65% $FB +2.6% (Down) $AXP -12.7% $LDRH -12.2% $RDUS -5.2% $SKX -3.4%
                      • Michael Blake Kuritz | Send Message 10 Jan

                        Great time to pick up more $FPRX $GERN $LGND #PartnershipsPrevail
                          • StockConsultant | Send Message 17 Dec 2015

                            $LGND confirmed breakout
                              • Chris Katje | Send Message 2 Dec 2015

                                Ligand Pharmaceuticals' Investor Day Reveals The 'Next 12', Strengthens Bullish Case $LGND
                                  • chicagomary | Send Message 10 Nov 2015

                                    What just happened to $LGND? buyout rumor? right after I sold 25 shares :(
                                      • Mayer Winkler | Send Message 19 Oct 2015

                                        All Eyes On October 23 For Spectrum And Ligand Investors $SPPI, $LGND
                                          Company Description
                                          Ligand Pharmaceuticals, Inc. is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Its products address the unmet medical needs of patients for a broad... More
                                          Sector: Healthcare
                                          Industry: Biotechnology
                                          Country: United States